Targeted drug therapy or "smart" drug delivery, potentially combined with simultaneous imaging modalities to monitor the delivery of drugs to specific tissues, is arguably the "holy grail" of pharmacology. Therapeutic approaches that exploit nanoparticles to deliver drugs 
Introduction
The use of nanoparticles in therapeutics, medical imaging and diagnostics is receiving considerable attention, as interdisciplinary research teams involving physicists and material chemists are increasingly combining their technologies and know-how with the biomedical community. 1 Numerous publications attest to the potential use of nanoparticles (whether organic, inorganic or metallic) in biomedical applications such as magnetic resonance imaging (MRI), 2 tissue repair and bone regeneration, 3 immunoassays, 4 detoxification of biological fluids, 5 hyperthermia, 6 and as drug delivery vehicles, 7 to name a few. This comprises the use of nanoparticles for theranostics, a novel field that combines diagnostic and therapeutic applications suitable for imaging and monitoring of individual patient's responses to therapy, paving the road towards personalized medicine. The concerns regarding the toxicological properties of nanoparticles are being addressed by an emerging community of nanotoxicologists, devoted to the thorough understanding of hazardous properties of nanoparticles (NPs) both in vitro and in vivo. 8 Procedures to mitigate toxicity, wherever it is found, are being applied. In addition, the environmental effect of NP production, their longterm impact in the environment, and regulatory issues are being tackled. Importantly, it will be necessary to categorize NPs and to assess each NP on a case-by-case basis in order to avoid inadequate generalizations that may hinder their commercial use including the application of NPs in medicine.
Among the biomedical applications of nanoparticles, their use in cancer therapeutics is the most anticipated. Irrespective of their composition, NPs easily penetrate cellular membranes through active and passive mechanisms due to their small size, allowing them to act as drug carriers with tunable pharmacokinetic properties, enabling slow or sustained release of their 4 payload. Of particular value to the oncology field is the potential use of NPs for targeted drug delivery, thus minimizing unwanted effects on bystander cells and tissues. This promises to reduce the toxicity of chemotherapeutic treatments by reducing the doses that are administered.
The enhanced permeability and retention (EPR) effect which has been widely observed for liposomes and other macromolecules appears to be also applicable to NPs of various forms.
This passive form of cell targeting relies on the diffusion limitation encountered by tumor growth of above a certain size (around 2 mm), which affects the intake of vital nutrients and oxygen. 9 In order to overcome this respiratory limitation, neo-angiogenesis occurs, resulting in an increased but usually immature tumor vasculature and lymph vasculature, which allows the penetration of nanoparticles below a certain size (approximately 2 µm), depending on the tumor type. Particles capable of penetrating through the interstitial tumor vasculature have considerably higher retention times than those in normal tissues, resulting in the EPR effect. 10, 11 The EPR effect is an important phenomenon that has been widely observed for all categories of NPs. In addition, active site-specific targeting and effective uptake of NPs has also been achieved via receptors on the cell membrane, which may mediate uptake through various phagocytic or endocytic mechanisms. To activate such receptors, a recognizable ligand needs to be tethered to the NP surface. Careful and efficient functionalization as well as encapsulating technologies for NPs has been developed over recent years, including biocompatible shells such as lipids, polymers, micelles or silica coatings of different kinds. In this context, folate mediated targeting holds substantial promise and has been one of the major strategies assimilated by the nanomedical field for targeted drug-delivery and imaging of tumors. 12 It is a daunting task to provide a comprehensive summary of the wide variety of NP architectures that have been investigated in recent years. Therefore, the aim of the current 5 commentary is merely to highlight some of the key aspects of folic acid mediated uptake, nanoparticle functionalization with folate linkers, and the current state-of-the-art for targeted imaging and drug delivery. We will also discuss nanoparticle-biomolecule interactions and whether the "holy grail" of targeted drug delivery based on the use of nanoparticles is, in fact, achievable.
Nanoparticles for biomedical applications
The European Union, a strong advocate for tighter control of chemical manufacturing, has initiated a serious discussion on the regulation of nanomaterials, and the following definition of nanomaterials from a regulatory perspective was recently proposed; 13 hence, nanomaterials:
(i) consist of particles, with one or more external dimensions in the size range 1 nm -100 nm for more than 1 % of their number size distribution;
(ii) have internal or surface structures in one or more dimensions in the size range 1 nm -100 nm;
(iii) have a specific surface area by volume greater than 60 m 2 /cm 3 , excluding materials consisting of particles with a size lower than 1 nm.
A particle is here defined as a minute piece of matter with defined physical boundaries as of ethylene glycol covalently to the external surface of the particle or reaction with fluorochromes prior to conjugation with folates is also easily achieved. 15 The latter is often necessary as organic NPs do not inherently offer any optical or detection properties.
Polymeric and lipid based NPs such as dendrimers or liposomes, offer the advantage of a relatively straightforward incorporation of drugs within their internal void or cavities, and the potential specific release in the affected area. 16 Micellar derived nanoparticles allow the encapsulation of hydrophobic drugs, since these rely on the amphiphilic behavior of surfactant molecules. This is of particular interest in cancer therapy as the formulation and delivery of poorly soluble drug lead compounds is a major hurdle in assessing their potential. Polymeric, non-ionic surfactants are already in wide use in the pharmaceutical industry as adjuvants.
Surfactants containing poly(ethylene oxide) chains have been found to prevent the recognition of the micelle by the reticuloendothelial system thus allowing for longer systemic circulation. 17 Zheng et al. 18 Unfortunately, in this study, the targeting properties of the particles were not evaluated. 26 The loading capacity of inorganic oxide nanoparticles can be improved through the introduction of pores within the particle. There are various methods of achieving this, but the most useful is to employ pore templating agents during the preparation of the NPs. 29 The preparation of ordered mesoporous silica relies on the use of surfactant and non-surfactant templates. [30] [31] [32] This method has been widely applied to prepare materials with varying porous structures, from 2-dimensional (2D)-cylindrical ordered pores to 3D cage type structures, with large surface areas (over 1000m 2 /g) and large pore volumes available for conjugation and loading of fluorophores, drugs, proteins, or folates. 33 Mesoporous materials have been the subject of numerous studies as drug delivery vehicles, and it has been shown that structural parameters such as pore connectivity, pore size, surface functionalization (hydrophobicity), and particle size can be altered in order to control the pharmacokinetic profile of drugs loaded within the pores.
7,34
Metallic NPs such as quantum dots (QDs) offer the potential to act as imaging agents due to their controllable light emission as a result of their tunable crystal size and semi-conductor properties. The same applies for gold NPs, where detection is based on their excellent light scattering and light absorption properties. Hence, such metallic NPs offer the advantage that no further detection molecule needs to be conjugated to the particle surface. However, it is difficult to conjugate folates (see following section) directly to the surface of metallic nanoparticles, as this often implies oxidation of the surface with a possible change in their optical properties. Therefore, amine and thiol terminated polyethylene glycol (PEG) groups 9 can be covalently reacted to metallic NP surfaces, thus offering an organic moiety capable of conjugation to folic acid, without altering the particle properties. The use of PEG chains on the surface of NPs have additional advantages as their presence reduces the amount of unspecific protein adsorption (opsonization) and has been found to drastically increase the blood circulation time as well as biodistribution of the particles.
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Finally, carbon nanotubes have also been investigated as drug or siRNA delivery vehicles in preclinical models, but it remains to be understood whether the benefits outweigh the potential risks. A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 mesothelioma, 37 endometrium/uterine 38 and particularly the ovary, while folate receptor beta or FOLR2 is a neutrophilic lineage marker and may be a promising target in myeloid leukaemia. 39 Expression of FOLR2 can be effectively induced by the differentiationpromoting effects of all-trans retinoic acid (ATRA) 40 . Thus, ATRA treatment of acute myelogenous leukaemia (AML) has been successfully combined with the simultaneous delivery of folate-receptor beta targeted nanoparticles. Expression of FOLRs often correlates with poor patient outcome 41 and has been deemed predictive for the therapeutic response to anti-cancer drugs such as cisplatin, 42 whilst their levels remain usually low in most normal cells and tissues (see Figure 2 ). The high expression of FOLR1 particularly in ovarian cancers led to its cloning from such tumors twenty years ago. 43 All three folate receptors are anchored to the plasma membrane via a glycosylphosphatidylinositol (GPI) tail, although soluble variants also exist. In fact, soluble folate receptors have been detected in blood, serum and ascites of cancer patients 44 and may thus be useful as biomarkers of disease in cancer patients.
Expression of FOLR1 and FOLR3 often correlate with the malignancy of different female genital tract malignancies 45 and have been useful as markers to distinguish ovarian from breast cancer metastases. 46 However, expression of FOLR1 is also high in normal kidney and placenta, which reflects the body's requirement to actively retain important vitamin-like cofactors such as folates, and to prevent their excretion. Furthermore, FOLR1 expression is high in normal lung tissue, which could relate to the rapid turnover of lung epithelial cells and/or tissue-specific protective effects exerted by folate-requiring mechanisms. Thus, lung, kidney and to some extent the placenta represent potential targets for therapy-related toxicity in any therapies that exploit folic acid for drug transport.
The ideal approach for the therapeutic exploitation of folate receptors in cancer treatment is the Trojan horse approach, whereby the FOLRs and the cellular receptor-mediated A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 endocytosis machinery are utilized as a portal of entry to deliver large payloads of chemotherapeutic drugs. Receptor-mediated endocytosis is a very effective, energyconsuming cellular import mechanism that utilizes the selectivity mechanisms provided by a series of unrelated receptors, combined with the ubiquitous clathrin-and/or caveolin endocytosis systems, to ensure the specificity of transport. Additionally, folate-targeted delivery can be combined with the use of membrane-translocating peptides such as the TAT protein of the human immunodeficiency virus 47 , which increases the likelihood to release the cargo by membrane disruption into the cytoplasm. FOLR1 expression often correlates directly with the activity of the intracellular folate cycle/1-carbon pathway and thymidine kinase, 48 and is co-expressed with metabolic genes required for oxidative respiration as a result of enhanced growth. Therefore, receptor-mediated endocytosis of folates/folate receptor conjugates could be combined with drugs that inhibit folate-related pathways (eg. A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 significant tumor-specific expression and utilize the same endocytosis route as FOLR1, may be highly rewarding for diagnostics, cancer imaging, and therapeutic applications of NPs.
Candidates such as the epidermal growth factor (EGF)/EGF receptor, Her-2/ERBB2, integrins, transferrin receptor, somatostatin/growth hormone receptor (GH/GHR), and glucose transporter (GLUT1) have been suggested. Some of these molecules are currently being targeted in clinical trials (reviewed in 50 ), although none of these trials utilize NPs. EGFR may be a particularly useful target, since many tumors such as head and neck cancers, glioblastomas, and lung adenocarcinomas strongly overexpress EGFR, but rarely show overexpression of FOLR1. 51 The utilization of cellular drug-entry ports into the cell provides unprecedented specificity of drug delivery that typically exceeds the uptake of free drugs by at least an order of magnitude. 52 This process significantly improves the direct bioavailability and reduces the toxicity of folate-conjugated drugs or NPs compared to free drugs, in particular for lipophilic drugs such as taxanes, doxorubicin, or even extremely hydrophobic derivatives such as SN-38, the active metabolite of irinotecan. 53 The delivery of siRNAs is another field of applications that would greatly profit from specificity. 54 Furthermore, the specificity of drug uptake can be easily monitored and quantitatively measured by competition with free folates/folic acid, a concept that can become very useful for mechanistic studies and optimization purposes. An alternative mechanism of active cellular uptake, independent of clathrin-coated pits, is mediated through the solute carrier protein SLC19A1 (RFC-1), which actively transports folates across a gradient into the cellular interior, in conjunction with a proton pump. The SLC19A1 carrier protein is occasionally upregulated in some cancers.
These two unrelated mechanisms, receptor-versus carrier-mediated import, may compete with each other on certain cell types, and this could explain the failure of folate uptake via 13 FOLR1 eg. in mesothelioma cells. 55 Considering the increasingly widespread experimental use of folates as bait for cancer drug delivery, the relative activity of these mechanisms has to be carefully elucidated.
Of course, it remains to be understood whether chronic treatment with folate-targeted NPs may lead to the downregulation of folate receptor expression and whether this will impact upon the efficacy of the approach. Experimental data addressing this topic are not available;
however, it is conceivable that resistance mechanisms related to the loss of FOLR1 surface expression could arise in patients undergoing NP-based therapies. The "escape" of cancer cells from FOLR1-targeted particles might be related to adaptation to folate deficiency, which is observed for instance under methotrexate treatment. Careful phenotyping of cancer cells from patients, to select those patients that are most likely to benefit from novel, targeted approaches will be needed.
Examples of folate-conjugated nanoparticles
There is no "one-size-fits-all" conjugation method for folates. The choice of strategy depends largely on the type of NP and on the specific function required. Broadly speaking, the preparation of folate-conjugated nanoparticles involves the following steps: (i) preparation of the folate linker (and/or detection group); (ii) preparation of the nanoparticle surface; (iii) reaction and purification. Two common folate linkers are shown in Figure 3 . Low and colleagues have described the preparation of folate linkers and the versatility of folic acid to accommodate varying tethering groups, without disturbing cellular uptake. 56 For example, the folate-ethylenediamine linker is easily conjugated with carboxyl groups on a NP surface.
Linkers may need further reaction or to be activated by N-hydroxysulfosuccinimide (NHS) or uptake by KB cells that overexpressed folate receptors than naked gold NPs. 57 The authors suggest the increased solubility (strictly speaking colloidal stability) over a pH range from 2 to 12 and electrolyte concentrations of up to 0.5 M NaCl as a possible reason for enhanced uptake.
There are several advantages of using NPs conjugated to folates, rather than using the therapeutic drugs directly conjugated to folate. First, the potential to deliver large quantities of drugs through individual receptor molecules and the utilization of the very effective receptormediated endocytosis pathway is especially feasible when combined with porous NPs or such particles that contain internal voids allowing large amounts of cargo to be transported. This is the case, for instance, in mesoporous silica nanoparticles, liposomes, polymeric spheres or dendrimers. 16, 17 This facilitates the use of drugs with less potency, but with higher efficacies due to improved pharmacokinetic behavior. It also allows the incorporation of lipophilic drugs that are difficult to deliver to the target tissue by standard intravenous or oral routes. 58 Additionally, NPs can be very useful to ascertain tight packaging of hydrophilic drug molecules which otherwise have a tendency to cause off-target effects due to percolation into irrelevant tissues. Such hydrophilic compounds may also have poor cell-and membrane penetrating properties. Moreover, the use of NPs in drug formulation may allow drug candidates that do not possess optimal solubility properties, to be encapsulated into 62 We have recently reported on a novel nonsurfactant route for the synthesis of highly ordered mesoporous materials, based on the supramolecular templating of stacked arrays of the tetramer-forming pterin groups of folic acid. 31, 63 This method leads to hexagonally ordered mesoporous structures with gyroid, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 16 to assess the biocompatibility and cellular targeting ability of these materials. Lu et al. have demonstrated that mesoporous silica nanoparticles materials are well tolerated by mice. 29 The maximum tolerated dose of the NPs was determined to be 100 mg/kg following intravenous administration. Biodistribution studies using human cancer xenografts revealed that the folateconjugated particles were taken up preferentially in tumors. In addition, the drug delivery
properties of mesoporous particles were demonstrated in vivo by delivery of camptothecin released from loaded mesoporous particles, resulting in a considerable decrease of tumor volume. 29 Mansoori et al. 64 have reported a comparative study of two folate-conjugated gold NPs using a variety of linkers (4-aminothiophenol and 6-mercapto-1-hexanol). The study provides an interesting analysis of folate receptor tissue distribution and particle endocytosis in cells with both high and low folate receptor expression (HeLa and MCF-7, respectively). The authors conclude that the type of conjugation has a direct effect on the cell death associated with the particles, with the 4-aminothiphenol linker being superior to the mercapto-1-hexanol linker.
Furthermore, this in vitro study clearly demonstrates the selectivity of some folate linker conjugates towards cells with high folate expression, and shows that 98% of the HeLa cells were killed after stimulating the particles with intense pulsed light after only four hours of incubation.
In sum, the abovementioned NPs appear to be the most promising candidates for future studies and clinical development as a result of their low toxicity, relatively facile and cost effective functionalization with folate conjugates through a variety of routes, improved pharmacokinetic behavior of the pharmaceutical agents, feasible diagnostic tools offering 
Other receptor-mediated pathways of uptake
As discussed above, the identification of additional ligand/receptor pairs that show significant tumor-specific expression could be highly rewarding. Byrne et al. Kaposi's sarcoma, brain tumors, melanoma, and bone metastases, and offers a further route for targeting. 67 A number of tumor signaling pathways, and nuclear and apoptotic receptors are reported as overexpressed to significant levels by tumor cells; [68] [69] [70] however, in many of these receptor targeting approaches the development of suitable antagonists is less developed than for those mentioned above and further research is needed in order to exploit their potential clinical use.
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Receptor-mediated endocytosis mostly occurs via clathrin-coated pits and vesicles, and requires a dedicated intracellular machinery of transport molecules such as arrestins, dynamins, and stabilins. An alternative system is represented by caveolin-dependent endocytosis, which utilizes lipid raft domains in the plasma membrane for forming caveolae, non-clathrin coated vesicles that nevertheless fuse with early endosomes and serve similar purposes. Internalization of particles may occur through additional, poorly understood mechanisms that utilize neither caveolae nor coated pits/vesicles. The ubiquity of the endocytosis processes, and the spectrum of diverse receptor/ligand pairs being transported and recycled via this regulated turnover, provides ideal mechanisms to be exploited or hijacked, eg. by naturally occurring viruses or by complex NP-based drug delivery systems.
Considerable efforts have been focused in recent years on the mode of uptake of NPs lacking specific ligands, such as folic acid. For instance, Zhang and Monteiro-Riviere 71 utilized 24 different endocytosis-interfering agents to investigate the mechanism by which QDs enter cells, and found that QD internalization is primarily regulated by the G-protein-coupled receptor-associated pathway and low density lipoprotein receptor/scavenger receptor pathways, whereas other endocytic pathways may play a minor role in the uptake of QDs.
Other investigators have shown that non-functionalized QDs may enter the nucleus in a sizeand surface charge-dependent manner. 72, 73 Chen and von Mikecz reported that silica nanoparticles translocate into the nucleus. 74 More recent spatio-temporal mapping of the uptake of silica particles of different sizes have disclosed that these NPs enter one by one engulfed in a vesicle, without evident involvement of classical-clathrin-coated pits;
endosomal structures were first occupied, and later lysosomes were populated, while no particles were found to reside in the nucleus or in other organelles. 75 Understanding how cells handle pristine NPs is of importance when specific pathways of uptake are exploited; The peptide targets tumors by binding integrins that are specifically expressed on the tumor vessel endothelium. They also showed that co-administration of iRGD enhances drug delivery and activity of drugs that are not chemically conjugated to it, including liposomes carrying doxorubicin. 79 Wong et al. 80 propose a multi-stage nanoparticle delivery system in which 100 nm nanoparticles "shrink" to 10 nm nanoparticles after they extravasate from the tumor vasculature and are exposed to the tumor microenvironment. The size-change of the nanoparticles is triggered by proteases that are highly expressed in the tumor microenvironment, which degrade the cores of 100 nm gelatin nanoparticles, releasing smaller
NPs from their surface. This interesting system, akin to a multi-stage rocket for space exploration, could provide a means to achieve deep tumor penetration of NPs and more effective treatment of cancer.
The biomolecular corona on nanoparticles
When NPs are presented to a physiological environment such as human plasma, they selectively absorb biomolecules (i.e. proteins, lipids) to form a so-called biomolecular corona on the surface of the NP. [81] [82] [83] [84] [85] In a recent study, the full repertoire of SPION-binding blood proteins was determined using a novel two-dimensional differential mass spectrometry approach. 88 The identified proteins showed specificity for surface domains of the NPs: mannan-binding lectins bound to the dextran coating, histidine-rich glycoprotein and kininogen bound to the iron oxide part, and other proteins were shown to be secondary binders. Interestingly, transferrin and albumin, the most abundant plasma proteins, showed no significant enrichment on the SPIONs. However, subsequent in vivo studies in mice suggested that the identified proteins did not play a significant role in the hepatic clearance of these NPs. 88 Importantly, both the dextran coat and the iron oxide core remained accessible to specific probes after incubation of SPIONs in plasma, suggesting that the NP surface could be "seen" by liver macrophages or by other cells, regardless of the protein coating. Notwithstanding, a better grasp of the nature of the biomolecule corona of NPs remains an important goal, as the adsorbed plasma proteins and 21 lipids could potentially determine the toxicity of nanomaterials, including their thrombogenic and complement-activating potential.
Conclusions and future perspectives
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This review discusses the benefits and limitations of folate-targeted nanoparticles for anticancer therapy. 
